BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30233772)

  • 21. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
    Servais S; Baron F; Beguin Y
    Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-γ mediates graft-versus-breast cancer effects via enhancing cytotoxic T lymphocyte activity.
    Zhao Q; Tong L; He N; Feng G; Leng L; Sun W; Xu Y; Wang Y; Xiang R; Li Z
    Exp Ther Med; 2014 Aug; 8(2):347-354. PubMed ID: 25009582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
    Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
    Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
    Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
    [No Abstract]   [Full Text] [Related]  

  • 27. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
    Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
    Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The allogeneic effect in non-Hodgkin's lymphoma.
    Goldstone AH; Kottaridis PD
    Leuk Lymphoma; 2003; 44 Suppl 3():S91-7. PubMed ID: 15202531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
    Bertaina A; Roncarolo MG
    Front Immunol; 2019; 10():1342. PubMed ID: 31354695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD3
    Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
    Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplantation Recipients.
    Yetmar ZA; Thoendel MJ; Bosch W; Seville MT; Hogan WJ; Beam E
    Transplant Cell Ther; 2023 Mar; 29(3):206.e1-206.e7. PubMed ID: 36526261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Autologous Hematopoietic Stem Cell Transplantation versus Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma: Systematic Review and Meta-Analysis.
    Liu X; Zheng Y; Li H; Wang M; You MJ; Tian C
    Oncology; 2023; 101(12):822-835. PubMed ID: 37598665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total Marrow Irradiation for Second Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia.
    Dominietto A; Vagge S; di Grazia C; Bregante S; Raiola AM; Varaldo R; Gualandi F; Gusinu M; Barra S; Agostinelli S; Angelucci E; Hui S
    Transplant Cell Ther; 2023 Aug; 29(8):506.e1-506.e6. PubMed ID: 37094701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
    Maris M; Storb R
    Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Allogeneic hematopoietic stem cell transplantations].
    Michallet M
    Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
    Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
    Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
    Front Immunol; 2020; 11():668. PubMed ID: 32431694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.